Abstract:We investigated the effects of bone mesenchymal stem cells (BMSCs) and different doses of glucocorticoid (GC) interventions on osteoporosis in systemic lupus erythematosus (SLE) murine models. Our resultsdemonstrated that BMSCs could effectively alleviate osteoporosis induced by SLE itself, as well as osteoporosis resulting from SLE combined with various doses of GC therapy. These findings may offer valuable guidance to clinicians regarding the use of BMSC treatment in SLE and provide insights into the judicious use of GCs in clinical practice. Objective Bone mesenchymal stem cells (BMSCs) have been tentatively applied in the treatment of glucocorticoid‐induced osteoporosis (GIOP) and systemic lupus erythematosus (SLE). However, the effects of BMSCs on osteoporosis within the context of glucocorticoid (GC) application in SLE remain unclear. Our aim was to explore the roles of BMSCs and different doses of GC interventions on osteoporosis in SLE murine models. Methods MRL/MpJ‐Faslpr mice were divided into eight groups with BMSC treatment and different dose of GC intervention. Three‐dimensional imaging analysis and hematoxylin and eosin (H&E) staining were performed to observe morphological changes. The concentrations of osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) in serum were measured by enzyme‐linked immunosorbent assay (ELISA). The subpopulation of B cells and T cells in bone marrows and spleens were analyzed by flow cytometry. Serum cytokines and chemokines were assessed using Luminex magnetic bead technology. Results BMSCs ameliorated osteoporosis in murine SLE models by enhancing bone mass, improving bone structure, and promoting bone formation through increased bone mineral content and optimization of trabecular morphology. BMSC and GC treatments reduced the number of B cells in bone marrows, but the effect was not significant in spleens. BMSCs significantly promoted the expression of IL‐10 while reducing IL‐18. Moreover, BMSCs exert immunomodulatory effects by reducing Th17 expression and rectifying the Th17/Treg imbalance. Conclusion BMSCs effectively alleviate osteoporosis induced by SLE itself, as well as osteoporosis resulting from SLE combined with various doses of GC therapy. The therapeutic effects of BMSCs appear to be mediated by their influence on bone marrow B cells, T cell subsets, and associated cytokines. High‐dose GC treatment exerts a potent anti‐inflammatory effect but may hinder the immunotherapeutic potential of BMSCs. Our research may offer valuable guidance to clinicians regarding the use of BMSC treatment in SLE and provide insights into the judicious use of GCs in clinical practice.

ActivatedNF-κBin Bone Marrow Mesenchymal Stem Cells from Systemic Lupus Erythematosus Patients Inhibits Osteogenic Differentiation Through Downregulating Smad Signaling

Enhanced Apoptosis And Senescence Of Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus

LPS-stimulated Inflammatory Environment Inhibits BMP-2-induced Osteoblastic Differentiation Through Crosstalk Between TLR4/MyD88/NF-κB and BMP/Smad Signaling.

Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-β Feedback Loop

Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus.

Mesenchymal stem cell therapy induces FLT3L and CD1c + dendritic cells in systemic lupus erythematosus patients

Bone Marrow-Derived Mesenchymal Stem Cells Inhibit T Follicular Helper Cell in Lupus-Prone Mice.

Abnormality of multilineage difierentiation potential of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus

Association of TNF-α with Impaired Migration Capacity of Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus.

Tumor Necrosis Factor-Alpha Inhibits Osteogenic Differentiation Of Pre-Osteoblasts By Downregulation Of Ephb4 Signaling Via Activated Nuclear Factor-Kappab Signaling Pathway

Dysregulation of the Mir-146A-smad4 Axis Impairs Osteogenesis of Bone Mesenchymal Stem Cells under Inflammation

The Supernatant of Bone Marrow from SLE Patients Promotes the Senescence of Mesenchymal Stem Cells

Apoptosis of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythem atosus

Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus

Activated B Lymphocyte Inhibited the Osteoblastogenesis of Bone Mesenchymal Stem Cells by Notch Signaling

Association of bone marrow mesenchymal stem cells and intracellular reactive oxygen species levels in patients with systemic lupus erythematosus

Combined application of mesenchymal stem cells and different glucocorticoid dosing alleviates osteoporosis in SLE murine models

Leptin and Neutrophil‐Activating Peptide 2 Promote Mesenchymal Stem Cell Senescence Through Activation of the Phosphatidylinositol 3‐kinase/akt Pathway in Patients with Systemic Lupus Erythematosus

TGF‐β Inhibits Osteogenesis by Upregulating the Expression of Ubiquitin Ligase SMURF1 Via MAPK‐ERK Signaling

THU0050 Leptin and Neutrophil Activating Protein 2 Promote Mesenchymal Stem Cells Senescence Through the Activation of Pi3k/Akt Pathway in Systemic Lupus Erythematosus

Sex differences in the therapeutic effect of unaltered versus NFκB sensing IL-4 over-expressing mesenchymal stromal cells in a murine model of chronic inflammatory bone loss